Safe and effective
drug therapy requires more of a medical assistant than simply handing over a prescription, or administering a drug to a patient.
The researchers caution that the reliable detection of small to moderate risks and benefits of
drug therapies requires cogent data from large - scale randomized trials designed a priori to test the hypothesis.
Certain medications and
drug therapies require pre-authorization by Manulife prior to the commencement of treatment.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount
required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS
Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the S
Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell
therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new
drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the S
drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other
therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
On both occasions I found alternatives to
drugs most helpful and the second time around,
required no
drug therapy at all.
Also, because the treatment is invasive —
requiring brain surgeons to drill into the skull and deliver the
therapy to the right spot in the brain — it should only be used by severely afflicted patients that don't respond to other
drugs.
The researchers believe that effective cancer
therapy in the future will
require the combined action of
drugs that target both the tumor and its adaptive responses to initial
therapies.
Just as chemotherapy often
requires several
drugs to combat resistance in cancerous cells, successful antimicrobial
therapy against some pathogens
requires a combination of
drugs.
For most of the past 20 years,
therapies for hepatitis C relied on interferon
drugs, which
require regular injections for as long as one year and trigger miserable, flu - like side effects that prompt many patients to quit the regimen.
Similarly, ethical concerns often
require researchers to test
drugs aimed at inducing tolerance in concert with immunosuppressive
therapy.
«We have learned a lot, and made advances, and we hope that we now have the tools to begin to chip away at the persistent virus that remains in patients, and
requires them to maintain lifelong antiviral
drug therapy,» said David Margolis, MD, Professor of Medicine at UNC and Principal Investigator of CARE.
In their report that has received advance online publication in Nature Nanotechnology, a research team based at the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH) describes how a nanomedicine that combines photodynamic
therapy — the use of light to trigger a chemical reaction — with a molecular
therapy drug targeted against common treatment resistance pathways reduced a thousand-fold the dosage of the molecular
therapy drug required to suppress tumor progression and metastatic outgrowth in an animal model.
Current
drug therapies for
drug - sensitive tuberculosis
require six to eight months of treatment; for
drug - resistant tuberculosis, treatment can take as long as two years.
The immune rejection that complicates organ transplants, and normally
requires long - term immunosuppressive
drug therapy, may also be treatable with CAAR T cell technology.
This system could, for example, enable single - administration vaccines that do not
require boosters as well as a new way to deliver chemotherapy, hormone
therapy, or
drugs that facilitate wound healing.
Treatment success rate of
drug - resistant tuberculosis in HIV - positive patients is low and
requires more effective regimen using new
drugs compatible with antiretroviral
therapy.
The problem with
drug substitution
therapy is that it's expensive and
requires daily trips to a clinic to receive the replacement
drug.
However, escitalopram
therapy is currently limited by the fact that some patients do not respond well to the
drug, while others develop adverse reactions
requiring discontinuation of treatment.
It is approved by the U.S. Food and
Drug Administration (FDA) for treating certain types of leukemia and is helpful in other conditions that
require immunosuppressive
therapy.
The US Food and
Drug Administration (FDA) recently approved the oral Bruton tyrosine kinase (BTK) inhibitor ibrutinib for the treatment of patients with relapsed or refractory marginal zone lymphoma who
require systemic
therapy and have had at least one prior anti-CD20
therapy.
• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study
drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C,
requiring antiviral
therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior
therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study
One problem is the long investment time needed for new
drugs or
therapies that
require FDA approval.
FDA Approved Ibrutinib for Relapsed, Refractory Marginal Zone Lymphoma: Approval for the use of ibrutinib in patients with relapsed or refractory marginal zone lymphoma was granted by the US Food and
Drug Administration for those patients who
require systemic
therapy who were treated with at least one anti-CD20
therapy.
Earlier research has found a connection between hormone replacement
therapy and asthma, but this study suggests that the
drug could result in severe asthma attacks, which could
require hospitalisation.
CoQ10 deficiency can result from deficiency of any of the seven vitamins
required for its synthesis, or by interference with its synthesis by cholesterol - lowering
drugs or hormone replacement
therapy (HRT).
The Pharmacy Services segment operates retail and mail order pharmacies, and specialty pharmacies for individuals that
require complex
drug therapies; designs and administers pharmacy benefit plans for its clients (including Medicare Part D services); and develops and operates Pharmacy Services information systems.
Managing patients with multiple medical and / or behavioral diagnoses may
require complex therapeutic interventions including combination
drug therapy.
Obstructions may
require surgical removal and potentially offensive
drug therapies must be changed, for example.
Cats with severe manifestations of feline heartworm disease may
require additional supportive
therapy, and may benefit from intravenous fluids, oxygen
therapy, cage confinement, bronchodilators (which expand the air passages of the lungs), cardiovascular
drugs, antibiotics and nursing care.
In certain situations your cat may
require fluid
therapy or antiemetics -
drugs to help control vomiting.
Dogs with fungal discospondylitis may
require lifelong treatment with antifungal
drugs.3 In cases of Brucella - positive dogs, combination
therapy consisting of doxycycline and an aminoglycoside is indicated.5 Corticosteroids are generally contraindicated because of possible impairment of the immune system.3
Cats that do not respond well to
drug therapy may
require dietary supplements containing high calorie levels, transfusions of blood (a process in which blood is given through an intravenous line to restore blood that has been lost) and intravenous fluid
therapy (fluid given to the cat through the veins to restore hydration).
After the obstruction has been relieved, treatment varies depending upon the condition of the cat and the kidney function but usually involve intravenous fluid
therapy, antibiotics, and
drugs that help restore bladder function are sometimes
required.
A combination of corticosteroids, other medications such as
drugs that open the airways (bronchodilators) and oxygen
therapy may be
required.
Also discusses behavioral modification techniques,
drug therapies and how to recognize when your dog
requires professional help.
We also offer
drug - free
therapies such as physical
therapy and laser
therapy to preserve the patient's strength and flexibility while reducing the amount of
drugs required to control your pet's pain during recovery.
These adjunctive
therapies may help minimize the doses of
drugs required to treat the condition, as well as help nourish and support overall heart health.
It may well be that the coming (and to some extent existing) revolution in genetically individualized medical
therapy will
require changes in how
drugs are evaluated, labeled, etc., but this is a singularity - driven issue that needs to be addressed by the policy branches of our government, and not haphazardly in product liability litigation.
The presiding judge made a treatment order under s. 672.58 of the Criminal Code,
requiring the accused to submit to anti-psychotic
drug therapy.
It is thus obvious that MS
requires a holistic therapeutic approach that takes into account
drug therapy, cognitive function, lifestyle behaviors and psychosocial factors (i.e., stress, coping, anxiety, depression, and self - efficacy).
In addition to
drug treatment, I will assess the person to see if additional services are
required, such as medical services, family
therapy, parenting support, and social and legal services,
Perhaps it comes from more choices for treatment (online, email
therapy, coaching, prescription
drugs) or a growing reluctance on many people's part to give permanent change the time and energy it
requires.
There's an idea in
therapy called a mandated client — one that is
required to attend
therapy as a result of a legal entanglement, a child abuse allegation, an incident of acting out or using
drugs in the context of work.
As Southeastern Wisconsin's leading, private, state - certified outpatient clinic addressing both mental health and alcohol /
drug abuse needs, we offer a complete range of specialized expertise, services, and locations to provide you the individualized
therapy and skills you
require to:
For example, depression and bipolar disorder (mood disorders) are very responsive to
drug therapy — substance abuse often
requires intervention and inpatient detoxification — personality disorders
require multi-year re-learning
therapies (e.g. DBT, Schema)-- Aspergers is often considered a long term disability.